CAS NO: | 1599440-13-7 |
规格: | 98% |
分子量: | 1034.05 |
包装 | 价格(元) |
100mg | 电议 |
50mg | 电议 |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
Background:
Deruxtecan, a toxin and linker moiety of DS-8201, is a drug-linker conjugate for antibody-drug conjugate (ADC) extracted from patent WO2017002776A1, compound 1. Drug-linker conjugates for ADC[1]
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window[2].
[1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1. [2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.